Outlook Therapeutics Inc (NASDAQ:OTLK) currently has a daily average trading volume of 1.48M but it saw 2408439 shares traded in last market. With a market cap of 39.27M USD, the company’s current market price of $1.66 came falling about -8.03 while comparing to the previous closing price of $1.80. In past 52 weeks, the stock remained buoying in the range of price level as high as $12.85 and as low as $0.87. In the recent trading on the day, stock has struck highest price mark of $1.595 while lowest mark touched by it was $1.85.
Taking a look at 20-day trading activity of Outlook Therapeutics Inc (OTLK) gives us an average price of $4.7005, while its current price level is -87.08% below from 52-week high level whereas it is 90.80% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.1412 while that of 200 days or SMA-200 reads an average of $7.1513. A closer look into the stock’s movement over the week reveals that its volatility is standing at 46.03% during that period while stretching the period over a month that decreases to 15.83%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 17.28 which implies that the stock is in oversold territory.
BTIG Research upgraded its recommendation for the stock as a “Buy” from “Neutral” on March 27, 2024 while assigning a price target of $50. Chardan Capital Markets issued its recommendations for the stock as it upgraded the price target for the stock is $3.
Over the week, OTLK’s stock price is moving -66.05% down while it is -72.61% when we observe its performance for the past one month. Year-to-date it is -78.93% down and over the past year, the stock is showing a downside performance of -81.00%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.94 beat the consensus estimate of -1.2 for the same. The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of -0.9 while estimate for next year EPS is -4.01.
Currently, Outlook Therapeutics Inc’s total number of outstanding shares is 23.41M. Stock’s beta reads 0.52. Its return on asset (ROA) is -205.48% on average.
